(Q51343168)

English

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

scientific article published on 22 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

author name string

Alessandro Ciresi

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Marco Calogero Amato

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Valentina Guarnotta

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Flavia Lo Castro

4

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

publication date

22 April 2013

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Clinical Endocrinology

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

79

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

845-852

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Advances in the treatment of prolactinomas

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Bone density in women with prolactinoma treated with dopamine agonists.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Body fat in men with prolactinoma

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Focus on prolactin as a metabolic hormone.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Prolactin: a diabetogenic hormone

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Hyperinsulinaemia in hyperprolactinaemic women.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Leptin in pituitary adenomas--a novel paracrine regulatory system.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Prolactinoma: a condition associated with hypoadiponectinemia

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Insulin sensitivity and hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Dopamine as a Prolactin (PRL) Inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

The dopamine D2 receptor (DRD2) as a major gene in obesity and height

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12204

21 January 2018

Identifiers

10.1111/CEN.12204

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/23506485

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51343168&oldid=1515687774"